We retrospectively evaluated a consecutive series of 45 patients (45 eyes) who underwent trabeculectomy augmented with a single intra-operative 5 minute application of 5-f1uorouracil (5-FU; 25 mg/m1). All patients were at an increased risk of subconjunctival fibrosis and surgical failure. The mean follow-up period was 24 months (range 12-42, SO 6.9). The mean pre operative intraocular pressure (lOP) was 29.1 mmHg (SO 6.1) and the mean lOP at the last post-opemtive visit was 16.6 mmHg (SO 6.4) (p < 0.0001) with a mean lOP reduction of 42%. The number of medications reduced from a mean of 2.3 (SO 0.7) pre-operatively, to 0.8 (SO 0.7) post-operatively (p < 0.0001) and 22 eyes (49%) required no topical treatment for lOP control. An lOP of 21 mmHg or less with or without medica tions was achieved in 80% of cases. There was no significant difference in final lOP or success rate over time between low-and high-risk patients, although the low-risk patients did better in the first 12-18 months. Complications included hypotony maculopathy in 2 cases (4%), leaking bleb in 5 cases (11%) and giant bleb in 1 case (2 %), giving a total of 8 cases (18 %) with bleb-related sequelae. In the short to medium term, a single per-operative application of 5-FU is a useful adjunctive treatment during glaucoma filtering surgery for low-to moderate-risk cases, although a steady increase in the failure rate was associated with increasing length of follow-up.
The most common cause of failure of glaucoma filtering surgery is the formation of excessive scar tissue beneath the conjunctiva, which occurs as a natural healing response to surgical trauma.1 This response is exaggerated in cases of previous ocular surgery, aphakia or uveItIs, and also where the patient is of a young age or of African or Asian race. Locally derived fibroblasts are thought to be the principal cellular component responsible for this reaction,1 and laboratory studies have shown that proliferation of these cells can be modified via the use of chemotherapeutic agents such as 5-fluorour acil (5-FU) and mitomycin C (MMCy?-4 Fluorouracil, a pyrimidine analogue, is an anti neoplastic agent which interferes with normal cell mitosis by competitively inhibiting the enzyme thymidilate synthetase and therefore the synthesis of DNA and RNA. 5 5-FU, when given by subcon junctival injection in the post-operative period, has been shown to increase the success rate of glaucoma filtering surgery in high-risk patients.6-9 Likewise, success rates are improved following the use of MMC applied intraoperatively.1O-14 However, MMC has a more profound inhibitory effect on subconjunctival fibroblasts than 5_FU1 5 and such filtering blebs tend to be extremely thin and avascular with the attendant risks of hypotony maculopathy l O,16 and bleb-related endophthalmitis ? 7 Administered post-operatively, 5-FU has several disadvantages, not least the need for repeated subconjunctival injections, which can be painful and inconvenient to the patient, and also an associated higher risk of corneal complications?8 More recently there has been a trend towards using 5-FU as a single exposure given at the time of surgery, largely based on the results of laboratory studies which suggested that a single intraoperative application would be as effective as repeated SUbconjunctival injections in inhibiting fibroblast proliferation?, 3 Recent clinical studies with limited follow-up (range 3-12 months) supported these findings, with success rates between 83 % and 91 %.19-21 Mora et al. 22 in a large study of 140 eyes with a mean follow-up of 16 months have Eye (1997) 11,663-671 © 1997 Royal College of Ophthalmologists also shown an impressive success rate « 21 mmHg, allowing medications) of 92%, with 72% having an lOP < 15 mmHg (and> 30% drop in lOP) at the last follow-up. However, in this study 56% of eyes had no increased risk of subconjunctival fibrosis. This retro spective study was undertaken to evaluate the long term efficacy and complications of intraoperative sponge 5-FU application in a group largely consisting of high-risk patients.
PATIENTS AND METHODS
A consecutive series of 45 eyes in 45 patients undergoing glaucoma filtration surgery with adjunc tive 5-FU was studied. There were 25 men and 20 women, all of whom were Caucasian apart from 4 women and 1 man of Asian origin. The mean age was 53.0 years (range 19-78, SD 15.8) and the mean follow-up period was 24 months (range 12-42, SD 6.9). Pre-and post-operative examination included visual acuity, lOP measurement by Gold mann applanation tonometry, slit lamp biomicro scopy and optic disc assessment using a +90 dioptre or +78 dioptre Volk lens. The pre-operative lOP was taken as the mean value of the last three recordings prior to surgery; the post-operative lOP was the value at the last follow-up visit. Visual field perimetry was performed at approximately yearly intervals post-operatively, using threshold (Humphrey, 24-2 program) and supra-threshold (Medmont, Gold mann and Friedmann) analysers.
Surgery was performed on the basis of an uncontrolled lOP despite maximally tolerated medi cal therapy. Two eyes with a pre-operative lOP of 21 mmHg and 19 mmHg were showing progressive optic nerve damage. There was a total of 5 surgeons (3 consultants and 2 senior registrars) who used a standardised surgical technique which included a limb ai-based conjunctival flap with or without exci sion of Tenon's capsule. A small surgical sponge (Sugi Steril, John Weiss) was trimmed and soaked in 5-FU 25 mg/ml (David Bull Laboratories, Warwick, UK) and then applied to the sclera which was covered with conjunctiva, taking care to try to avoid contact between the cut conjunctival edge and the sponge. The sponge was left in place for 5 minutes and was replenished with 1 or 2 drops of 5-FU every minute using an insulin syringe and a 25 gauge needle. Following this the sclera was thoroughly irrigated with 20 ml normal saline. A one-third to one-half thickness rectangular scleral flap measuring 4 mm X 3 mm was then dissected into clear cornea and a block of corneoscleral tissue measuring 3 mm x 1 mm was excised followed by a peripheral iridectomy. The scleral flap was sutured with two 10/0 monofilament nylon sutures and the conjunctiva was closed with interrupted 10/0 monofilament nylon or continuous 8/0 vicryl sutures.
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Post-operative medications included topical dexa methasone 0.1 % applied 6-8 times daily and chloramphenicol eye drops 4 times a day. Topical steroids were tailed off slowly over a period of 3 months. Post-operative examinations and measure ments were made at 1 day, 1 week, 1 month, 3 months, 6 months and then 6 monthly, or between these times if the clinical situation demanded. Laser suture lysis was performed within the first 2 weeks depending on the lOP and the appearance of the bleb.2 3 Additional subconjunctival 5-FU injections (2.5 mg via a 30-gauge needle into the bleb) were given if there were signs of bleb failure within the first 21 post-operative days. The criteria for surgical outcome were defined as follows: A Wilcoxon matched-pairs signed-rank test was used to evaluate the intra-individual changes in lOP and the pre-operative to post-operative change in anti-glaucoma medications. A Kaplan-Meier analysis was performed to assess how success changed over 6 monthly intervals using three criteria: complete success, unqualified success and IOP<15 mmHg. A comparison of the survival curves between the low-and high-risk groups for the three success criteria was undertaken using the log rank test. In addition any pre-operative to post-operative change in optic disc cupping and visual field loss was documented.
RESULTS
Patient details, including causes of glaucoma and risk factors for surgical failure, are summarised in Table I . Thirty-five patients were at high risk of subconjunctival fibrosis and therefore surgical fail ure, with many patients having more than one risk factor. There were 10 cases which were in the low risk category. Fig. 1 shows a scatter plot of the pre-and post operative lOPs. The mean pre-operative lOP was 29.1 mmHg (range 19-48, SD 6.1) and the mean post-operative lOP at the last follow-up was 16.6 mmHg (range 7-37, SD 6.4) (p < 0.0001). Com plete success was achieved in 22 eyes (49%) and qualified success in 14 eyes (31 %), giving an unqualified success rate of 80%. Nine eyes (20%) have failed, 6 of which were in the high-risk group and 3 in the low-risk group (Table I) . One of these underwent a further 5-FU trabeculectomy at the time of last follow-up. The mean number of medications pre-operatively was 2.3 (SD 0.7) reducing to 0.8 (SD 0.7) post-operatively (p < 0.0001). Twenty-three patients (51 %) required topical treatment at the last follow-up, 20 of whom were in the high-risk group and 3 in the low-risk group. Table II illustrates the lOP reduction for the different risk groups and the group as a whole, and also the success rates for the three different criteria at the time of last follow up.
The Kaplan-Meier survival curve for trabeculect amy with per-operative sponge 5-FU is shown in Fig.  2 . Survival varies according to the criteria used to define success. Fig. 3 compares the survival curves between low-risk and high-risk eyes for the three different success criteria. There was no significant difference in the survival curves between the two groups (complete success, log rank 1.38; unqualified success, log rank 0.24; lOP < 15 mmHg and> 30% reduction in lOP, log rank 0.09; significance;;': 2.0).
Argon laser suture lysis was performed to augment bleb formation in the early post-operative period in 4 eyes. Six eyes in the high-risk group showing evidence of early bleb failure required post-operative subconjunctival injections of 5-FU. The number of injections ranged between two and five. Of those eyes that required post-operative subconjunctival 5-FU, 1 eye failed at 4 months, 2 eyes failed at 18 months and the remaining 2 eyes remain con trolled on a topical [3-blocker alone. Visual field tests were performed in 30 of 45 patients (67%). Perimetry was not performed in those patients whose visual acuity was too poor for meaningful field assessment. The types of perimeter used were as follows: Medmont, 14 cases; Humphrey (24-2 program), 6; Goldmann, 5; Friedmann, 5. Only 2 patients showed evidence of deterioration in the visual fields. The first was a 72-year-old man with primary open angle glaucoma (POAG) who demon strated progression of superior and inferior arcuate scotomas 2 years post-operatively in the presence of good lOP controL The lOP at 2 years was 8 mmHg and did not rise above 14 mmHg throughout follow up. The second patient was a 78-year-old woman with POAG who also demonstrated progression of upper and lower arcuate scotomas at the 12 month follow-up visit in the presence of an lOP below 15 mmHg. One patient showed documented evidence of progression of glaucomatous disc damage following surgery. This was a 19-year-old man with severe uveitic glaucoma and poor lOP control whose optic disc cupping over a 2Vz year period deteriorated from a cup-to-disc ratio of 0.9 to an end-stage cup in the presence of a reduction in visual acuity from 6/12 to 6/60. Table III summarises the complications encoun tered. There were no serious bleb-related or corneal complications amongst those patients requiring post operative subconjunctival injections of 5-FU. Hypo tony maculopathy was seen in 2 eyes, 1 of which settled spontaneously 2 weeks post-operatively. The second case required four surgical procedures to revise the bleb, the last of which was combined with a phacoemulsification with foldable intraocular lens implant through a separate clear corneal incision. The lOP at the last follow-up was 11 mmHg on no topical medication with a visual acuity of 6/6. There was 1 case of leaking bleb 5 days post-operatively which settled spontaneously after 6 days, and 1 case of persistent corneal epithelial defect which lasted for 1 year. This, however, was in a patient who had had a previous corneal graft for Acanthamoeba keratitis.
Amongst the late complications there was 1 case of delayed epithelial defect occurring 3 months post operatively which settled after 6 weeks. There were 4 cases of leaking bleb, 1 at 1 year which resolved spontaneously, another which required refashioning of the conjunctiva 9 months post-operatively and 2 which were described as transconjunctival pinpoint leaks which were observed. About half the blebs (49%) were described as cystic, 1 of which was a giant bleb overhanging the cornea (initially a Tenon's cyst) which did not require surgical revision. There were no cases of bleb-related endophthalmitis. Retinal detachment occurred in 2 eyes: an aphakic eye in which there was vitreous loss at the time of trabeculectomy and a myopic pseudophakic eye.
Cataract occurred in 4 cases, 1 of which was progression of pre-existing lens opacities; 3 of these cases underwent successful phacoemulsification with lens implantation. At the last follow-up, visual acuity was within 1 line or better than pre-operative levels in 41 of 45 eyes (Table I) . Of the 4 cases with a deterioration in visual acuity, there were 2 retinal detachments (6/9 to CF, and CF to PL), 1 posterior subcapsular cataract (6/9 to 6/18) that has not yet required surgery and 1 case of chronic uveitis with progression of glaucoma (6/12 to 6/60).
DISCUSSION
Blumenkratz was the first to use 5-FU in ophthal mology in 1982 for the treatment of experimental vitreoretinopathy. It has since gained wide accep tance as a useful antiproliferative agent in glaucoma surgery. Initially applied as a series of post-operative injections, it was not until the early 1990s that the per-operative application of 5-FU on a sponge was first suggested. The rationale was that by applying the drug directly to the sclera, only the target tissues would be exposed to maximal drug concentration, and thereby the incidence of 5-FU related complica tions would be expected to be reduced. The unqualified success rate (lOP < 21 mmHg with or without medications) of 80% in this group of largely high-risk patients compares favourably with the pilot study of Lanigan et al. 19 (91 % unqualified success rate) where the maximum follow-up was only 9 months. Traditionally the arbitrary figure of 20 or 21 mmHg has been used as the target pressure by which success is defined, but it is now recognised that lower lOPs (i.e. in the low teens) are considered to be desirable for optic nerves already damaged by glaucoma. The third criterion for outcome, i.e. an lOP < 15 mmHg and> 30% reduction, as used by Mora et ai.,22 therefore provides the most realistic assessment of the value of per-operative 5-FU in high-risk patients. Table II demonstrates that at last follow-up, this goal is being achieved in only 47% of eyes (n = 21), one third of which (n = 7) required topical medication. If those patients requiring topical medication are excluded, then by the strictest definition of outcome (lOP < 15 mmHg and> 30% reduction, without medication) the success rate falls to 31 % (n = 14).
The Kaplan-Meier curve (Fig. 2) shows that at 33 months post-operatively, using the most lenient criterion, the success rate is maintained at 77%. However, if the more stringent criteria are applied there is a steady drop-out as more eyes fail to survive, until at 33 months only 25 % are maintaining an lOP < 15 mmHg and> 30% reduction. It would appear, therefore, that the longer the post-operative period, the greater the failure rate, and over the longer term the ability to maintain a low lOP amongst a high number of patients is disappointing. The Kaplan-Meier statistics do, however, become less reliable as the post-operative interval increases, due to the fact that the success rates are calculated
from fewer patients and therefore any failures produce a much greater proportional loss of survival. It is interesting to note that there was no significant difference in the long-term survival between the low risk and high-risk groups, although the low-risk group tended to fare better within the first 12-18 months. It should also be noted that the number in the low-risk group was small (n = 10), making comparison less meaningful.
Comparison with the study of Mora et al. 22 is difficult because approximately half the patients in that study had no increased risk for surgical failure. If these 'low-risk' patients are excluded, they would still appear to have slightly more favourable results, with 90% achieving an lOP < 21 mmHg (allowing medi cations) and 62% achieving an lOP < 15 mmHg with > 30% drop in lOP (allowing medications). It should be noted, however, that the follow-up period in this study was shorter than in our study (mean 16 months, range 2-42) where the minimum follow-up was 12 months; the concentration of 5-FU used was 50 mg/ml compared with 25 mg/ml in the current study; and 29% of their patients had a pre-operative lOP of less than 21 mmHg. Accurate comparison is also hampered by the variation in risk profile of the different patient groups. For example, all high-risk patients were included in the current 5-FU study whereas in the study by Mora et al. some of the very high-risk patients were assigned to MMC trabecu lectomy and therefore not represented in their results.
By way of comparison with intraoperative sponge MMC for high-risk patients, there is a lack of published data examining the success in achieving lOPs in the low teens, even in the short term. Skuta et al.14 found that in 20 eyes, 60% achieved an lOP of 12 mmHg or less at 6 months, and 74% were medication free. These figures are comparable with those of Mora et al?2 using sponge 5-FU (62% lOP < 15 mmHg with> 30% reduction, 70% medication free) and would appear to be superior to the results of this study (47% lOP < 15 mmHg and > 30% reduction, 49% medication free) bearing in mind the short length of follow-up. At the 6 month follow-up visit in this study our equivalent figures are 71 % lOP < 15 mmHg (and> 30% reduction) with 76% medi cation free.
Although the primary endpoint of the study was lOP control rather than preservation of visual function, visual acuity and visual field data were analysed, accepting the limitations of recording data in a retrospective study. Computerised automated perimetry has done much to improve the assessment of a patient's visual status, although a simple, accurate and economically viable method of both high specificity and sensitivity for early detection of significant change in an individual's visual field has yet to be developed. In view of these problems, control of lOP has traditionally been used as the main criterion for success. Measurement of lOP is easy, accurate, reproducible and objective, and provides data that are easily analysed statistically. The term 'success' is therefore synonymous with surgical success rather than disease control, although a lower lOP cut-off level is likely to bring pressure control in line with disease control.
The fact that 33% (n = 15) of patients were unable to perform a useful field test reflects an advanced state of visual impairment. This high degree of pre operative damage reduces the ability to detect a treatment effect. Despite this, visual acuity was well maintained (within 1 Snellen line or better) in 91 % (n = 41) of patients and only 2 of the 30 patients who performed perimetry demonstrated progression of arcuate scotomas at 12 and 24 months post-opera tively, both of whom maintained lOPs at or below 15 mmHg. Clinical estimation of progression of glaucomatous optic disc cupping is even less reliable in a retrospective case note analysis when one is reliant on the subjective assessment of cup-to-disc ratios (CDR) and the variable artistic skills of a number of different doctors, rather than serial optic disc photographs. There was nevertheless documen ted progression of optic disc cupping (CDR 0.9 to 1.0) in only 1 case, this being in a 19-year-old man with severe uveitic glaucoma and poorly controlled lOP whose visual acuity dropped from 6/12 to 6/60 over 2Yz years of follow-up.
There was a low rate of corneal complications, with only 2 eyes (4 %) developing epithelial defects. Corneal epithelial cells are particularly susceptible to the effects of 5-FU, and the incidence of corneal related problems appears to be much greater with the use of subconjunctival injections, rates varying between 29% and 64% depending on the dose of 5-FU used.18,32 This could be attributable to the fact that 5-FU applied per-operatively remains relatively localised to the area of application and is then rapidly washed away during irrigation. Thorough irrigation following application of the sponge minimises the risk of 5-FU entering the anterior chamber when creating the ostium, thus avoiding toxicity to the corneal endothelium,33 the lens33 and the ciliary body. In contrast, following a subconjunctival injec tion, 5-FU can leach out of the puncture site into the pre-corneal tear film, thereby remaining in contact with the corneal epithelium for several hours.
Late bleb leaks were detected in 4 eyes (9%), in addition to 1 case occurring within the first week. By taking care to avoid contact between the cut conjunctival wound edge and the sponge, and by meticulous suturing of the conjunctiva, the incidence of wound dehiscence and wound leaks in the early post-operative period can be minimised. Antimetabolite administration per se does not cause a wound leak in the early post-operative period, since the wound should be held watertight by the suture regardless of the degree of healing; however, it will unmask an inadequately closed wound. The inci dence of bleb leak in this study was considerably lower than the 25-35% reported by other studies using post-operative injections.18,34 Ocular hypotony associated with maculopathy was seen in 2 patients (4 %) in the early post-operative period. In 1 case this persisted for many months and required several surgical revisions to the bleb before a successful outcome in terms of visual recovery (6/6) and lOP control (11 mmHg) was achieved. Prata et al. 3 5 found hypotonous maculopathy in 4.1 % of all their MMC treated eyes compared with an incidence of 1.3% in eyes treated with post-operative 5-FU. Long-term hypotony is a potentially serious complication34,36,37 and permanent visual impairment may result from chronic macular changes. Young myopic eyes appear to be most at risk, perhaps due to low scleral rigidity?7 Giant bleb, which overhangs the cornea, is another long-term bleb-related complication which often gives rise to a persistent foreign body sensation and ocular surface disturbance. The single case encountered in this series did not require surgical excision?6
Late bleb-related endophthalmitis is a potentially devastating complication which has been reported following the use of 5-FU given post-operatively, at rates varying between 1.9% and 9.4%. 7,34,36,38 These are high rates for such a severe complication and it is interesting to note the higher figure of 9.4% resulted from inferiorly located blebs.38 It is encouraging, therefore, to report that there were no cases of bleb infection or endophthalmitis from this series, although nearly 50% of the blebs were described as cystic. Whilst it has been shown that lower lOPs are achieved with the use of adjunctive 5-FU in patients undergoing primary filtration surgery,34,39 the presence of these large thin-walled cystic blebs undoubtedly represents a potential route of entry for bacterial pathogens and thus infection remains a risk.
A relatively high incidence of bleb-related sequelae (8 cases, 18%) was noted in this study. These comprised leaking bleb in 5 cases, hypotony maculopathy in 2 cases and giant bleb in 1 case. This has been the experience of other studies after filtering operations with post-operative 5_FU.6--9,34,36,38,39 The increased incidence of bleb-related sequelae suggests a relative weakening of the bleb wall, most likely due to the toxic effect of 5-FU on the existing activated fibroblasts which has been reported experimentalll-4 as well as in human eyes after trabeculectomy.4o
In an era of peri-operative use of antimetabolites such as 5-FU and MMC, the possibility of late 
